Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hata T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31. Cancer Chemother Pharmacol. 2013. PMID: 23543294 Clinical Trial.
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: fukunaga m. Oncology. 2013;85(6):317-22. doi: 10.1159/000356018. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247419 Clinical Trial.
Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study.
Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M, Ueshima S, Kitani K, Hasegawa J, Tamagawa H, Fujii M, Ohkawa A, Kato T, Morita S, Fukuzaki T, Mizushima T, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Hata T, et al. Surg Today. 2014 Nov;44(11):2116-23. doi: 10.1007/s00595-014-0911-7. Epub 2014 May 20. Surg Today. 2014. PMID: 24840400 Free PMC article.
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Nishimura J, et al. Among authors: fukunaga m. Eur J Cancer. 2015 Jul;51(10):1274-82. doi: 10.1016/j.ejca.2015.03.024. Epub 2015 Apr 24. Eur J Cancer. 2015. PMID: 25922233 Clinical Trial.
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T, Tamagawa H, Matsuda C, Murata K, Fukunaga M, Ota H, Hasegawa J, Tsujie M, Fukuzaki T, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: fukunaga m. Oncology. 2015;89(3):152-8. doi: 10.1159/000381718. Epub 2015 May 8. Oncology. 2015. PMID: 25967649 Clinical Trial.
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Yamamoto H, Murata K, Fukunaga M, Ohnishi T, Noura S, Miyake Y, Kato T, Ohtsuka M, Nakamura Y, Takemasa I, Mizushima T, Ikeda M, Ohue M, Sekimoto M, Nezu R, Matsuura N, Monden M, Doki Y, Mori M. Yamamoto H, et al. Among authors: fukunaga m. Clin Cancer Res. 2016 Jul 1;22(13):3201-8. doi: 10.1158/1078-0432.CCR-15-2199. Epub 2016 Feb 1. Clin Cancer Res. 2016. PMID: 26831719
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim HM, Kudo T, Murata K, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Mizushima T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2017 Jul;80(1):81-90. doi: 10.1007/s00280-017-3336-3. Epub 2017 May 16. Cancer Chemother Pharmacol. 2017. PMID: 28510802 Clinical Trial.
Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer.
Yamamoto H, Tei M, Uemura M, Takemasa I, Uemura Y, Murata K, Fukunaga M, Ohue M, Ohnishi T, Ikeda K, Kato T, Okamura S, Ikenaga M, Haraguchi N, Nishimura J, Mizushima T, Mimori K, Doki Y, Mori M. Yamamoto H, et al. Among authors: fukunaga m. Int J Oncol. 2013 Feb;42(2):549-55. doi: 10.3892/ijo.2012.1750. Epub 2012 Dec 21. Int J Oncol. 2013. PMID: 23258614
1,294 results